Treadwell Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
41 Madison Ave Fl 25, New York City, New...Website
www.treadwelltx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells vulnerabilities to develop small molecules. Treadwell Therapeutics was founded in 2019 and is headquartered in New York, New York.Explore more
Treadwell Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Treadwell Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Treadwell Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Treadwell Therapeutics had a recent Job posting/layoffs
Check out if Treadwell Therapeutics is spiking on competitors!
Check if Treadwell Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Treadwell Therapeutics recently announced quarterly report
Product Launch: Get notified when Treadwell Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Treadwell Therapeutics
Treadwell Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Treadwell Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Treadwell Therapeutics
Compare insights from companies similar to Treadwell Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Treadwell Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Treadwell Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Treadwell Therapeutics.
Treadwell Therapeutics financials insights
Gather financial insights about Treadwell Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$27M
2021
Series B
$91M
Treadwell Therapeutics Tech Stack
A closer look at the technologies used by Treadwell Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Treadwell Therapeutics has announced that J.D. Mowery, Chief Operating Officer, has left the organization to join KBI Biopharma and Selexis as Chief Executive Officer.
Open Position
New Hire
Executive Move
Open Position
Open Position
Treadwell Therapeutics News & Media
Treadwell Announces the Formation and Members of Scientific Advisory Board
TORONTO & SAN FRANCISCO--(BUSINESS WIRE)--Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the formation of a Scientific Advisory Board comprised of prominent oncology leaders and drug developers. The SAB will work closely with Treadwell to advance the company’s pipeline of small molecules, biologics and cell therapies. “We are delighted and honored to be working withTreadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer. Dr. Sidhu is a...Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps1), for the treatment of adult patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy, both as a monotherapy and in combination with fulTreadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers, today announced a presentation for the Company's CFI-400945 program, a first in class inhibitor of Polo-like...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Treadwell Therapeutics
Sign Up For FreeTo access detailed company insights
Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells vulnerabilities to develop small molecules. Treadwell Therapeutics was founded in 2019 and is headquartered in New York, New York.... Read More
